Journal: Journal of Nanobiotechnology

Article Title: Peptide-modified phase-transition nanoparticles co-deliver FTO siRNA and Ce6 for sonodynamic metabolism-immunotherapy of melanoma

doi: 10.1186/s12951-025-03872-3

Figure Lengend Snippet: Gene silencing and glycolytic regulation of si-Ce6@tLyp-1-NPs. ( A ) Effect of UTMD in vitro ( B ) CEUS mode, n = 3 ( C ) Schematic illustration of the B16F10 cells treated with si-Ce6@tLyP-1-NPs combined with US ( D ) CLSM observation of the localization of FAM-siRNA in B16-F10 cells after transfection with free siRNA, si-Ce6@NPs(+), si-Ce6@tLyP-1-NPs (+). The scale was 10 μm, and Phalloidin was the cytoskeleton. DAPI is the nucleus. ( E ) The relative mRNA expression of FTO in different groups of B16-F10 ( F , G ) The protein expression of FTO in different groups of B16-F10. ( H ) Volcano plot of DEGs. ( I ) Heat map of genes involved in the glycolytic pathway. ( J) Representative pathways enriched in the identified genes as determined by GSEA (NES= −1.4016, p-value = 0.0424). ( K , L ) The mRNA expression levels of HK2 and PGAM1 in the control group and B16-F10 cells treated with different methods. ( M ) Representative western blot images of HK2 and PGAM1 expression in control and treated B16-F10 cell groups. ( N , O ) Quantitative analysis of HK2 and PGAM1 protein expression. ( P ) Lactate levels in cell culture medium were measured

Article Snippet: CRT antibody (IF:1:300, 27298-1), FTO antibody (WB:1:2000, IHC:1:300, 68111-1), PGAM1 antibody (WB:1:2000, 16126-1) were obtained from Proteintech (Wuhan, China).

Techniques: In Vitro, Transfection, Expressing, Control, Western Blot, Cell Culture

Journal: Clinical and Translational Medicine

Article Title: The noncoding and coding transcriptional landscape of the peripheral immune response in patients with COVID‐19

doi: 10.1002/ctm2.200

Figure Lengend Snippet: Identification of biomarker miRNAs by small RNA‐sEquation. (A) Research experimental design. We collected red blood cell‐depleted whole blood from moderate, severe COVID‐19 patients and healthy donors. Small RNA‐seq and rRNA depleted‐seq were performed. Biomarker and therapeutic target miRNAs were identified and validated with co‐analysis of mRNAs and lncRNAs and combination of scRNA‐seq data. Transcriptome during viral infection was studied. (B) UpSet plot shows the number of DEmiRs with eight different expression tendencies. The box and line charts show the tendency of each group. The arrows point out the position of biomarker miRNAs. (C) The heatmap shows the expression levels of the biomarker miRNAs in four specific DEmiR expression tendency. (D‐G) Expression of biomarker miRNAs in each sample. Each plot is colored by donor of origin. The X axes accord with the COVID‐19 status of each donor: M (n = 6), S (n = 6), and H (n = 4). The P ‐values are exact two‐sided generated by one‐way ANOVA with post hoc comparisons by Tukey's test. Boxplot features: minimum whisker, the smallest value within; minimum box, 25th percentile; center, median; maximum box, 75th percentile; maximum whisker, the largest value within. (D) miRNAs consistently downregulated. (E) miRNAs consistently upregulated. (F) miRNAs only upregulated in severe COVID‐19 patients. (G) miRNAs only downregulated in severe patients. (H) GO‐term functional enrichment by biological progress for the predicted target genes of three representative miRNAs

Article Snippet: Erythrocytes were removed from human whole blood with Erythrocyte lysis buffer (Cat. No.: AR1118, BOSTER).

Techniques: Biomarker Discovery, RNA Sequencing, Infection, Expressing, Generated, Whisker Assay, Functional Assay